Gujarat Kidney and Super Speciality Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 19, 2026
- Posted by: Kunal Singla
- Category: News
The Gujarat Kidney and Super Speciality share price target 2026 is Rs 120, implying approximately 20 percent upside from the current market price of Rs 100 (NSE: GUJAKIDNEY). With Q4 FY26 results released in 2026 and Specialty Healthcare and Nephrology tailwinds in focus, the Rs 120 price objective is supported by the FY27 earnings recovery thesis.
Gujarat Kidney and Super Speciality (NSE: GUJAKIDNEY) is a Specialty Healthcare and Nephrology company trading at Rs 100 with a market capitalisation of Rs 500 crore. Analysts have set the Gujarat Kidney and Super Speciality share price target at Rs 120 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.
Click Here – Get Free Investment Predictions
Gujarat Kidney and Super Speciality Share Price Target 2026: Key Takeaways
- Gujarat Kidney and Super Speciality share price target 2026: Rs 120 (20% upside from CMP Rs 100)
- Bull case: Rs 145 | Bear case: Rs 80
- Ticker: GUJAKIDNEY | Sector: Specialty Healthcare and Nephrology | MCap: Rs 500 crore
- 52W range: Rs 69 to Rs 184 | PE: 25x
- Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
- Key risk: FY27 earnings miss or FII outflows from Indian equities
Gujarat Kidney and Super Speciality Company Overview
Gujarat Kidney and Super Speciality (NSE: GUJAKIDNEY) is a Gujarat-based nephrology and super-speciality hospital chain providing kidney transplant, dialysis, and renal care services, with growing patient volumes from CKD prevalence in India. At CMP Rs 100 against a 52 week range of Rs 69 to Rs 184, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 500 crore with trailing PE of 25x. Compared to peers in specialty hospitals like Krishna Institute of Medical Sciences, Gujarat Kidney and Super Speciality is positioned as a potential re-rating candidate toward the Rs 120 price objective on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | GUJAKIDNEY |
| Sector | Specialty Healthcare and Nephrology |
| CMP (2026) | Rs 100 |
| 52 Week High | Rs 184 |
| 52 Week Low | Rs 69 |
| Market Cap | Rs 500 crore |
| Trailing PE | 25x |
| 12-Month Analyst Target | Rs 120 |
| Bull Case Target | Rs 145 |
| Bear Case Target | Rs 80 |
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks now on Univest
Why Is the Gujarat Kidney and Super Speciality Share Price Target Set at Rs 120 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The Gujarat Kidney and Super Speciality share price target of Rs 120 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating. The Rs 120 price objective represents the base case with FY27 execution as the key variable.
Structural Sector Tailwinds in Specialty Healthcare and Nephrology
The Specialty Healthcare and Nephrology sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Gujarat Kidney and Super Speciality’s position among peers in specialty hospitals like Krishna Institute of Medical Sciences creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 145 bull case to materialise.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Gujarat Kidney and Super Speciality’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 120 analyst consensus.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Gujarat Kidney and Super Speciality’s Specialty Healthcare and Nephrology operations, improving the probability of achieving the Rs 120 price objective through FY27 earnings delivery.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 25x PE, Gujarat Kidney and Super Speciality is positioned as a beneficiary of institutional reallocation, providing a tailwind toward the Rs 145 bull case over the medium term.
Gujarat Kidney and Super Speciality Share Price Targets: Short Term, 12 Month, and Long Term
Short Term Gujarat Kidney and Super Speciality Share Price Target
Near-term support for Gujarat Kidney and Super Speciality is anchored close to the 52 week low of Rs 69. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors can use the 52 week low as an entry reference while awaiting FY27 earnings confirmation.
12-Month Gujarat Kidney and Super Speciality Share Price Target 2026
The 12-month Gujarat Kidney and Super Speciality share price target 2026 is Rs 120, implying approximately 20 percent upside from CMP Rs 100. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Track live on NSE ticker GUJAKIDNEY.
Long Term Gujarat Kidney and Super Speciality Share Price Target: FY27 to FY28
The long term Gujarat Kidney and Super Speciality share price target for FY27 to FY28 is Rs 145 in the bull case, requiring full earnings delivery, re-rating among peers in specialty hospitals like Krishna Institute of Medical Sciences, and sustained institutional buying over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for Gujarat Kidney and Super Speciality in 2026
Bull Case Gujarat Kidney and Super Speciality Share Price Target: Rs 145
The bull case Gujarat Kidney and Super Speciality share price target of Rs 145 materialises when FY27 earnings beat analyst estimates, Specialty Healthcare and Nephrology tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 100, this represents approximately 45 percent potential upside.
Bear Case Gujarat Kidney and Super Speciality Share Price Target: Rs 80
The bear case Gujarat Kidney and Super Speciality share price target of Rs 80 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 69.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 145 | FY27 beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 120 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 80 | FY27 miss, guidance cut, FII outflows persist |
Key Risks That Could Derail the Gujarat Kidney and Super Speciality 2026 Price Objective
Global Macro and US Tariff Headwinds
Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Gujarat Kidney and Super Speciality share price target of Rs 120, with FII outflows being the direct transmission mechanism to Indian equity valuations.
FY27 Earnings Miss and Guidance Risk
An FY27 earnings miss or downward guidance revision would compress valuation multiples. This is the most direct company-specific risk to the Rs 120 analyst price objective. Investors must monitor quarterly results and management commentary closely.
Competitive Intensity Among Specialty Healthcare and Nephrology Peers
Intensifying competition from peers in specialty hospitals like Krishna Institute of Medical Sciences could compress Gujarat Kidney and Super Speciality’s market share and pricing power. This structural risk must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 120 analyst target for 2026.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.
How to Invest in Gujarat Kidney and Super Speciality
Check the Univest Screener for live data
Before considering any investment based on the Gujarat Kidney and Super Speciality share price target of Rs 120, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Specialty Healthcare and Nephrology sector demand.
Open a Demat account with a SEBI registered stockbroker to trade Gujarat Kidney and Super Speciality (NSE: GUJAKIDNEY) with regulatory protection. Study the competitive landscape among peers in specialty hospitals like Krishna Institute of Medical Sciences before executing any position.
Plan your entry using the 52 week low of Rs 69 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 120 price objective. Always set a stop loss below the 52 week low.
Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track Gujarat Kidney and Super Speciality’s live share price and receive daily stock recommendations.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on Gujarat Kidney and Super Speciality Share Price Target 2026
What is the Gujarat Kidney and Super Speciality share price target for 2026?
Ans. The Gujarat Kidney and Super Speciality share price target 2026 is Rs 120, implying approximately 20 percent upside from CMP Rs 100. Bull case is Rs 145, bear case is Rs 80.
What was the Gujarat Kidney and Super Speciality share price target for 2025?
Ans. The 2025 price objective for Gujarat Kidney and Super Speciality was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 120, reflecting FY27 growth potential from CMP Rs 100.
Is Gujarat Kidney and Super Speciality a good investment at Rs 100?
Ans. At Rs 100, Gujarat Kidney and Super Speciality offers potential upside toward Rs 120 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance and portfolio goals. Consult a SEBI registered financial advisor before investing.
What are the key risks to the Gujarat Kidney and Super Speciality share price target 2026?
Ans. Key risks to the Gujarat Kidney and Super Speciality share price target of Rs 120 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Specialty Healthcare and Nephrology. Monitoring quarterly results is essential.
What is the 52 week high and low of Gujarat Kidney and Super Speciality?
Ans. The 52 week high of Gujarat Kidney and Super Speciality is Rs 184 and the 52 week low is Rs 69. At CMP Rs 100, the stock is below its 52 week high and offers potential upside toward the Rs 120 price objective.
What are the main growth catalysts for Gujarat Kidney and Super Speciality in 2026?
Ans. Key catalysts include FY27 PAT recovery, Specialty Healthcare and Nephrology sector tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does Gujarat Kidney and Super Speciality compare to its peers?
Ans. Gujarat Kidney and Super Speciality operates in Specialty Healthcare and Nephrology alongside peers in specialty hospitals like Krishna Institute of Medical Sciences. At CMP Rs 100 with MCap Rs 500 crore, it is a potential re-rating candidate toward the Gujarat Kidney and Super Speciality share price target of Rs 120 on FY27 delivery.
What is the Gujarat Kidney and Super Speciality share price target for 2027?
Ans. The long-term Gujarat Kidney and Super Speciality share price target for FY27 to FY28 is Rs 145 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.
